Albert Beckers

List of Publications by Citations

214 papers	10,118 citations	56 h-index	95 g-index
229 ext. papers	11,638 ext. citations	5.2 avg, IF	5.9 L-index

#	Paper	IF	Citations
214	High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 4769-75	5.6	693
213	Pituitary incidentaloma: an endocrine society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism*, **2011**, 96, 894-904	5.6	341
212	Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 457-65	5.6	335
211	Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 2518-22	5.6	317
210	Cabergoline in the treatment of acromegaly: a study in 64 patients. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 374-8	5.6	282
209	Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, E373-83	5.6	259
208	Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 1891-6	5.6	243
207	Risk factors and causes of death in MEN1 disease. A GTE (Groupe dREtude des Tumeurs Endocrines) cohort study among 758 patients. *World Journal of Surgery*, **2010**, 34, 249-55	3.3	234
206	Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. *Endocrine Reviews*, **2013**, 34, 239-77	27.2	232
205	Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. *New England Journal of Medicine*, **2014**, 371, 2363-74	59.2	220
204	The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. *European Journal of Endocrinology*, **2005**, 152, 645-54	6.5	219
203	The epidemiology of prolactinomas. *Pituitary*, **2005**, 8, 3-6	4.3	190
202	Clinical characterization of familial isolated pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 3316-23	5.6	182
201	The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 1577-85	5.6	154
200	Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 99-104	5.6	154
199	The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. *Clinical Genetics*, **2010**, 78, 457-63	4	146
198	The clinical, pathological, and genetic features of familial isolated pituitary adenomas. *European Journal of Endocrinology*, **2007**, 157, 371-82	6.5	131

197	Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. *European Journal of Endocrinology*, **2012**, 167, 651-62	6.5	130
196	Classical pituitary tumour apoplexy: clinical features, management and outcomes in a series of 24 patients. *Clinical Neurology and Neurosurgery*, **2007**, 109, 63-70	2	130
195	High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. *European Journal of Endocrinology*, **2011**, 165, 509-15	6.5	124
194	The epidemiology and genetics of pituitary adenomas. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2009**, 23, 543-54	6.5	124
193	Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. *European Journal of Endocrinology*, **2005**, 152, 61-6	6.5	123
192	Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients. *Endocrine-Related Cancer*, **2015**, 22, 745-57	5.7	119
191	Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. *Endocrine-Related Cancer*, **2009**, 16, 1029-43	5.7	115
190	Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. *Journal of Clinical Endocrinology and Metabolism*, **2007**, 92, 1952-5	5.6	112
189	X-linked acrogigantism syndrome: clinical profile and therapeutic responses. *Endocrine-Related Cancer*, **2015**, 22, 353-67	5.7	110
188	Acromegaly at diagnosis in 3173 patients from the Liﬁe Acromegaly Survey (LAS) Database. *Endocrine-Related Cancer*, **2017**, 24, 505-518	5.7	110
187	Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don℟ forget MEN1 genetic analysis. *European Journal of Endocrinology*, **2013**, 168, 533-41	6.5	110
186	Cabergoline and the risk of valvular lesions in endocrine disease. *European Journal of Endocrinology*, **2008**, 159, 1-5	6.5	106
185	Mutation Analysis of the MEN1 Gene in Multiple Endocrine Neoplasia Type 1, Familial Acromegaly and Familial Isolated Hyperparathyroidism. *Journal of Clinical Endocrinology and Metabolism*, **1998**, 83, 2621-2626	5.6	102
184	Hypogonadism in a patient with a mutation in the luteinizing hormone beta-subunit gene. *New England Journal of Medicine*, **2004**, 351, 2619-25	59.2	100
183	Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 3413-20	5.6	95
182	Pituitary Disease in MEN Type 1 (MEN1): Data from the France-Belgium MEN1 Multicenter Study. *Journal of Clinical Endocrinology and Metabolism*, **2002**, 87, 457-465	5.6	92
181	Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry. *European Journal of Endocrinology*, **2017**, 176, 645-655	6.5	89
180	Therapy of endocrine disease: outcomes in patients with Cushing℟ disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. *European Journal of Endocrinology*, **2015**, 172, R227-39	6.5	89

179	Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'Etude des Tumeurs Endocrines. *European Journal of Endocrinology*, **2011**, 165, 97-105	6.5	89
178	Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients		89
177	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	88
176	Reproduction, smell, and neurodevelopmental disorders: genetic defects in different hypogonadotropic hypogonadal syndromes. *Frontiers in Endocrinology*, **2014**, 5, 109	5.7	83
175	Thyrotropin-secreting pituitary adenomas: report of seven cases. *Journal of Clinical Endocrinology and Metabolism*, **1991**, 72, 477-83	5.6	80
174	Placental and pituitary growth hormone secretion during pregnancy in acromegalic women. *Journal of Clinical Endocrinology and Metabolism*, **1990**, 71, 725-31	5.6	80
173	Light and electron microscopic immunolocalization of bovine pregnancy-associated glycoprotein in the bovine placentome. *Biology of Reproduction*, **1992**, 46, 623-9	3.9	77
172	Long-term outcome of patients with acromegaly and congestive heart failure. *Journal of Clinical Endocrinology and Metabolism*, **2004**, 89, 5308-13	5.6	75
171	Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. *European Journal of Endocrinology*, **2007**, 157, 383-91	6.5	74
170	Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d'Etude des Tumeurs Endocrines (GTE) cohort study. *Human Molecular Genetics*, **2013**, 22, 1940-8	5.6	68
169	Multidisciplinary management of acromegaly: A consensus. *Reviews in Endocrine and Metabolic Disorders*, **2020**, 21, 667-678	10.5	67
168	The genetics of pituitary adenomas. *Best Practice and Research in Clinical Endocrinology and Metabolism*, **2010**, 24, 461-76	6.5	66
167	Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. *Journal of Clinical Endocrinology and Metabolism*, **2005**, 90, 841-8	5.6	62
166	Presurgical Octreotide: treatment in acromegaly. *Metabolism: Clinical and Experimental*, **1996**, 45, 72-4	12.7	62
165	Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. *Endocrine-Related Cancer*, **2012**, 19, 233-41	5.7	61
164	The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. *Journal of Bone and Mineral Research*, **2002**, 17, 1081-94	6.3	61
163	The treatment of sporadic versus MEN1-related pituitary adenomas. *Journal of Internal Medicine*, **2003**, 253, 599-605	10.8	61
162	Somatic mosaicism underlies X-linked acrogigantism syndrome in sporadic male subjects. *Endocrine-Related Cancer*, **2016**, 23, 221-33	5.7	59

161	Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases. *Human Mutation*, **1999**, 13, 54-60	4.7	57
160	Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. *Endocrine-Related Cancer*, **2015**, 22, 169-77	5.7	56
159	Presurgical octreotide treatment in acromegaly. *Metabolism: Clinical and Experimental*, **1992**, 41, 51-8	12.7	56
158	Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation. *Endocrine-Related Cancer*, **2011**, 18, 347-56	5.7	55
157	Two years of replacement therapy in adults with growth hormone deficiency. *Clinical Endocrinology*, **1997**, 47, 485-94	3.4	54
156	The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. *Journal of Clinical Endocrinology and Metabolism*, **2010**, 95, 3745-9	5.6	52
155	Cabergoline for Cushing's disease: a large retrospective multicenter study. *European Journal of Endocrinology*, **2017**, 176, 305-314	6.5	51
154	Parathyroid carcinoma: Challenges in diagnosis and treatment. *Annales D'Endocrinologie*, **2015**, 76, 169-77	1.7	50
153	MANAGEMENT OF ENDOCRINE DISEASE: Pituitary 'incidentaloma': neuroradiological assessment and differential diagnosis. *European Journal of Endocrinology*, **2016**, 175, R171-84	6.5	49
152	T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. *Endocrine-Related Cancer*, **2016**, 23, 871-881	5.7	47
151	GHRH excess and blockade in X-LAG syndrome. *Endocrine-Related Cancer*, **2016**, 23, 161-70	5.7	45
150	McCune-Albright syndrome: a detailed pathological and genetic analysis of disease effects in an adult patient. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E2029-38	5.6	45
149	Pheochromocytomas and pituitary adenomas in three patients with exon deletions. *Endocrine-Related Cancer*, **2018**, 25, L37-L42	5.7	43
148	Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. *International Journal of Cancer*, **2009**, 125, 2122-6	7.5	43
147	Familial acromegaly: case report and review of the literature. *Pituitary*, **1999**, 1, 273-7	4.3	42
146	Familial isolated pituitary adenomas (FIPA) and mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. *Endocrinology and Metabolism Clinics of North America*, **2015**, 44, 19-25	5.5	41
145	Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene. *European Journal of Endocrinology*, **2009**, 161, 799-804	6.5	41
144	Expression of Somatostatin Receptor SST4 in Human Placenta and Absence of Octreotide Effect on Human Placental Growth Hormone Concentration during Pregnancy. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 3771-3776	5.6	41

143	Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. *Endocrine-Related Cancer*, **2013**, 20, 753-66	5.7	40
142	The causes and consequences of pituitary gigantism. *Nature Reviews Endocrinology*, **2018**, 14, 705-720	15.2	39
141	Familial pituitary adenomas. *Journal of Internal Medicine*, **2009**, 266, 5-18	10.8	38
140	Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome. *Endocrine*, **2016**, 51, 236-44	4	37
139	Epidemiology and Management Challenges in Prolactinomas. *Neuroendocrinology*, **2019**, 109, 20-27	5.6	35
138	The Epidemiology of Pituitary Adenomas. *Endocrinology and Metabolism Clinics of North America*, **2020**, 49, 347-355	5.5	34
137	Comparative densitometric study of iliac crest and scapula bone in relation to osseous integrated dental implants in microvascular mandibular reconstruction. *Journal of Cranio-Maxillo-Facial Surgery* , **1998**, 26, 75-83	3.6	34
136	Autonomously functioning thyroid nodules in a patient with a thyrotropin-secreting pituitary adenoma: possible cause--effect relationship. *European Journal of Endocrinology*, **1994**, 131, 355-8	6.5	34
135	Clinical and genetic features of familial pituitary adenomas. *Hormone and Metabolic Research*, **2005**, 37, 347-54	3.1	31
134	Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment. *International Journal of Cancer*, **2007**, 121, 1245-52	7.5	30
133	Cyclical Cushing's disease and its successful control under sodium valproate. *Journal of Endocrinological Investigation*, **1990**, 13, 923-9	5.2	30
132	AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. *Endocrine Connections*, **2019**, 8, 367-377	3.5	30
131	The third/second generation PTH assay ratio as a marker for parathyroid carcinoma: evaluation using an automated platform. *Journal of Clinical Endocrinology and Metabolism*, **2014**, 99, E453-7	5.6	29
130	T2-weighted MRI signal intensity as a predictor of hormonal and tumoral responses to somatostatin receptor ligands in acromegaly: a perspective. *Pituitary*, **2017**, 20, 116-120	4.3	28
129	Medical treatment in Cushing's syndrome: dopamine agonists and cabergoline. *Neuroendocrinology*, **2010**, 92 Suppl 1, 116-9	5.6	28
128	A vital region for human glycoprotein hormone trafficking revealed by an LHB mutation. *Journal of Endocrinology*, **2016**, 231, 197-207	4.7	26
127	Characterization of GPR101 transcript structure and expression patterns. *Journal of Molecular Endocrinology*, **2016**, 57, 97-111	4.5	25
126	The burden of illness of hypopituitary adults with growth hormone deficiency. *Pharmacoeconomics*, **1998**, 14, 395-403	4.4	25

125	Variable regions of chromosome 11 loss in different pathological tissues of a patient with the multiple endocrine neoplasia type I syndrome. *Journal of Clinical Endocrinology and Metabolism*, **1994**, 79, 1498-1502	5.6	24
124	Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. *Journal of Clinical Pharmacology*, **2014**, 54, 1308-17	2.9	23
123	Screening for GPR101 defects in pediatric pituitary corticotropinomas. *Endocrine-Related Cancer*, **2016**, 23, 357-365	5.7	22
122	Genetic, molecular and clinical features of familial isolated pituitary adenomas. *Hormone Research in Paediatrics*, **2009**, 71 Suppl 2, 116-22	3.3	22
121	Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma. *European Journal of Endocrinology*, **2019**, 181, K21-K27	6.5	22
120	The epidemiology and management of pituitary incidentalomas. *Hormone Research in Paediatrics*, **2007**, 68 Suppl 5, 195-8	3.3	21
119	Breast cancer in a male-to-female transsexual patient with a BRCA2 mutation. *Endocrine-Related Cancer*, **2016**, 23, 391-7	5.7	20
118	MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. *European Journal of Endocrinology*, **2017**, 176, 323-328	6.5	19
117	Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening. *Pituitary*, **2016**, 19, 507-14	4.3	19
116	Resistant Paediatric Somatotropinomas due to AIP Mutations: Role of Pegvisomant. *Hormone Research in Paediatrics*, **2018**, 90, 196-202	3.3	19
115	Pituitary gigantism: Causes and clinical characteristics. *Annales D'Endocrinologie*, **2015**, 76, 643-9	1.7	19
114	Familial pituitary tumor syndromes. *Endocrine Practice*, **2011**, 17 Suppl 3, 41-6	3.2	19
113	Genetics of Cushing's syndrome. *Neuroendocrinology*, **2010**, 92 Suppl 1, 6-10	5.6	19
112	Does preoperative somatostatin analog treatment improve surgical cure rates in acromegaly? A new look at an old question. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 2975-7	5.6	19
111	Somatic and germline mutations in the pathogenesis of pituitary adenomas. *European Journal of Endocrinology*, **2019**, 181, R235-R254	6.5	19
110	Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia. *Endocrine*, **2017**, 55, 239-245	4	18
109	Higher prevalence of clinically relevant pituitary adenomas confirmed. *Clinical Endocrinology*, **2010**, 72, 290-1	3.4	18
108	French consensus on the management of acromegaly. *Annales D'Endocrinologie*, **2009**, 70, 92-106	1.7	18

107	Thyrotoxic adenoma followed by atypical hyperthyroidism due to struma ovarii: clinical and genetic studies. *European Journal of Endocrinology*, **2004**, 150, 431-7	6.5	18
106	Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium. *Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders*, **2004**, 3, 77-81		18
105	Paleogenetic study of ancient DNA suggestive of X-linked acrogigantism. *Endocrine-Related Cancer*, **2017**, 24, L17-L20	5.7	17
104	Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference. *Neuroradiology*, **2015**, 57, 679-84	3.2	17
103	Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene. *Arquivos Brasileiros De Endocrinologia E Metabologia*, **2010**, 54, 761-7		17
102	Testicular effects of isolated luteinizing hormone deficiency and reversal by long-term human chorionic gonadotropin treatment. *Journal of Clinical Endocrinology and Metabolism*, **2009**, 94, 3-4	5.6	17
101	Skin tensile properties in patients treated for acromegaly. *Dermatology*, **2002**, 204, 325-9	4.4	17
100	Immunocytochemical evidence for production of luteinizing hormone and follicle-stimulating hormone in separate cells in the bovine. *Biology of Reproduction*, **1991**, 45, 788-96	3.9	17
99	GPR101 Mutations are not a Frequent Cause of Congenital Isolated Growth Hormone Deficiency. *Hormone and Metabolic Research*, **2016**, 48, 389-93	3.1	17
98	Conversion to Graves disease from Hashimoto thyroiditis: a study of 24 patients. *Archives of Endocrinology and Metabolism*, **2018**, 62, 609-614	2.2	17
97	A novel inactivating mutation of the LH/chorionic gonadotrophin receptor with impaired membrane trafficking leading to Leydig cell hypoplasia type 1. *European Journal of Endocrinology*, **2015**, 172, K27-36	6.5	16
96	The Liege Acromegaly Survey (LAS): a new software tool for the study of acromegaly. *Annales D'Endocrinologie*, **2012**, 73, 190-201	1.7	16
95	Tensegrity and type 1 dermal dendrocytes in acromegaly. *European Journal of Clinical Investigation*, **2005**, 35, 133-9	4.6	16
94	AIP and MEN1 mutations and AIP immunohistochemistry in pituitary adenomas in a tertiary referral center. *Endocrine Connections*, **2019**, 8, 338-348	3.5	16
93	Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study. *World Journal of Surgery*, **2018**, 42, 143-152	3.3	16
92	Pituitary MRI in Cushing's disease - an update.. *Journal of Neuroendocrinology*, **2022**, e13123	3.8	15
91	Screening for genetic causes of growth hormone hypersecretion. *Growth Hormone and IGF Research* , **2016**, 30-31, 52-57	2	14
90	Genetic susceptibility in pituitary adenomas: from pathogenesis to clinical implications. *Expert Review of Endocrinology and Metabolism*, **2011**, 6, 195-214	4.1	14

89	Pharmacokinetic study of a new testosterone-in-adhesive matrix patch applied every 2 days to hypogonadal men. *Journal of Steroid Biochemistry and Molecular Biology*, **2008**, 109, 177-84	5.1	14
88	Familial colloid cyst of the third ventricle: neuroendocrinological follow-up and review of the literature. *Clinical Neurology and Neurosurgery*, **2002**, 104, 367-70	2	14
87	Clinical and genetic aspects of familial isolated pituitary adenomas. *Clinics*, **2012**, 67 Suppl 1, 37-41	2.3	13
86	Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. *Clinical Endocrinology*, **2003**, 58, 572-80	3.4	13
85	GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of G and G. *Nature Communications*, **2020**, 11, 4752	17.4	13
84	Genetic factors in the development of pituitary adenomas. *Endocrine Development*, **2010**, 17, 121-133		12
83	Treatment of pituitary tumors: somatostatin. *Endocrine*, **2005**, 28, 93-100		12
82	Effect of treatment with octreotide on the morphology of growth hormone-secreting pituitary adenomas: Study of 24 cases. *Endocrine Pathology*, **1991**, 2, 123-131	4.2	12
81	Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	11
80	Update on familial pituitary tumors: from multiple endocrine neoplasia type 1 to familial isolated pituitary adenoma. *Hormone Research in Paediatrics*, **2009**, 71 Suppl 1, 105-11	3.3	11
79	miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance. *International Journal of Cancer*, **2020**, 147, 3523-3538	7.5	11
78	Familial pituitary adenomas. *Annales D'Endocrinologie*, **2010**, 71, 479-85	1.7	10
77	125I-Tyr0-hCRH labelling characteristics of corticotropin-releasing hormone receptors: differences between normal and adenomatous corticotrophs. *Neurochemistry International*, **1997**, 30, 291-7	4.4	9
76	Pseudomalabsorption of thyroid hormones: case report and review of the literature. *Annales D'Endocrinologie*, **2007**, 68, 460-3	1.7	9
75	Vitex agnus castus might enrich the pharmacological armamentarium for medical treatment of prolactinoma. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, **2007**, 135, 139-40	2.4	9
74	AIP mutations and gigantism. *Annales D'Endocrinologie*, **2017**, 78, 123-130	1.7	8
73	Overview of genetic testing in patients with pituitary adenomas. *Annales D'Endocrinologie*, **2012**, 73, 62-4	1.7	8
72	Hyperfunctioning unilateral adrenal macronodule in three patients with Cushing's disease: hormonal and imaging characterization. *European Journal of Endocrinology*, **1993**, 129, 284-90	6.5	8

71	Contrast behavior between microadenoma and normal pituitary gland after gadolinium injection as a function of time at 1.5 T. *Neuroradiology*, **1992**, 34, 184-9	3.2	8
70	Deletion of exons 1-3 of the MEN1 gene in a large Italian family causes the loss of menin expression. *Familial Cancer*, **2014**, 13, 273-80	3	7
69	Human anti-animal antibodies interference in the Siemens Immulite chemiluminescent insulin immuno-assay: about one case. *Clinica Chimica Acta*, **2011**, 412, 668-9	6.2	7
68	Diagnosis of primary thyrotrophin-secreting microadenoma by 1.5 T MR. *European Journal of Radiology*, **1992**, 14, 18-21	4.7	7
67	Acute effects of Parlodel-LAR and response to long-term treatment with bromocriptine in a patient with a follicle stimulating hormone-secreting pituitary adenoma. *Journal of Endocrinological Investigation*, **1991**, 14, 135-8	5.2	7
66	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: The roles of AIP and GPR101 in familial isolated pituitary adenomas (FIPA). *Endocrine-Related Cancer*, **2020**, 27, T77-T86	5.7	7
65	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: GPR101, an orphan GPCR with roles in growth and pituitary tumorigenesis. *Endocrine-Related Cancer*, **2020**, 27, T87-T97	5.7	7
64	Clinical and Molecular Update on Genetic Causes of Pituitary Adenomas. *Hormone and Metabolic Research*, **2020**, 52, 553-561	3.1	7
63	X-LAG: How did they grow so tall?. *Annales D'Endocrinologie*, **2017**, 78, 131-136	1.7	6
62	Long-term remission of disseminated parathyroid cancer following immunotherapy. *Endocrine*, **2020**, 67, 204-208	4	6
61	How to recognize Cowden syndrome: A novel PTEN mutation description. *Annales D'Endocrinologie*, **2017**, 78, 188-190	1.7	5
60	Pituitary Disease in Mutation-Positive Familial Isolated Pituitary Adenoma (FIPA): A Kindred-Based Overview. *Journal of Clinical Medicine*, **2020**, 9,	5.1	5
59	Pancreatic Neuroendocrine Neoplasm Associated with a Familial MAX Deletion. *Hormone and Metabolic Research*, **2020**, 52, 784-787	3.1	5
58	High prevalence of autoimmune thyroid diseases in patients with prolactinomas: A cross-sectional retrospective study in a single tertiary referral centre. *Annales D'Endocrinologie*, **2016**, 77, 37-42	1.7	5
57	A clinically novel AIP mutation in a patient with a very large, apparently sporadic somatotrope adenoma. *Endocrinology, Diabetes and Metabolism Case Reports*, **2014**, 2014, 140048	1.4	5
56	Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor. *Archives of Endocrinology and Metabolism*, **2017**, 61, 506-509	2.2	5
55	The association of astrocytoma and pituitary adenoma in a patient with alcaptonuria. *Journal of the Neurological Sciences*, **1992**, 108, 32-4	3.2	5
54	Primary hypertrophic osteoarthropathy due to a novel mutation masquerading as acromegaly. *Endocrinology, Diabetes and Metabolism Case Reports*, **2017**, 2017,	1.4	5

53	Association between mixture of persistent organic pollutants and thyroid pathologies in a Belgian population. *Environmental Research*, **2020**, 181, 108922	7.9	5
52	Persistent low levels of serum hCG due to heterophilic mouse antibodies: an unrecognized pitfall in the diagnosis of trophoblastic disease. *Gynecological Endocrinology*, **2016**, 32, 439-41	2.4	4
51	Acromegaly and sleep apnea: cephalometric evaluations. *Annales D'Endocrinologie*, **2011**, 72, 211-7	1.7	4
50	Pituitary adenomas in young patients: when should we consider a genetic predisposition?. *Expert Review of Endocrinology and Metabolism*, **2009**, 4, 529-531	4.1	4
49	Management of acromegaly. *F1000 Medicine Reports*, **2010**, 2, 54		4
48	Expression of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) in Non-Somatotroph Pituitary Tumours and the Effects of PPARα Agonists on MMQ Cells. *Hormone and Metabolic Research*, **2018**, 50, 640-647	3.1	3
47	Genetics of Pituitary Tumor Syndromes **2017**, 619-630		3
46	Mutations of calcium-sensing receptor gene: two novel mutations and overview of impact on calcium homeostasis. *European Journal of Endocrinology*, **2011**, 165, 353-8	6.5	3
45	The effect of naloxone and metoclopramide on the secretion of luteinizing hormone in a hyperprolactinemic hypogonadotropic postmenopausal woman. *Fertility and Sterility*, **1995**, 64, 969-71	4.8	3
44	Compound heterozygous mutations in the luteinizing hormone receptor signal peptide causing 46,XY disorder of sex development. *European Journal of Endocrinology*, **2019**, 181, K11-K20	6.5	3
43	Acromegaly in the setting of Tatton-Brown-Rahman Syndrome. *Pituitary*, **2020**, 23, 167-170	4.3	3
42	Clinical Biology of the Pituitary Adenoma.. *Endocrine Reviews*, **2022**,	27.2	3
41	Adipsic diabetes insipidus revealing a bifocal intracranial germinoma. *Annales D'Endocrinologie*, **2017**, 78, 141-145	1.7	2
40	ENDOCRINOLOGY AND ART. The acromegalic voice of Tango: Don Edmundo Rivero. *Journal of Endocrinological Investigation*, **2015**, 38, 1023-4	5.2	2
39	Neuroimaging of aggressive pituitary tumors. *Reviews in Endocrine and Metabolic Disorders*, **2020**, 21, 235-242	10.5	2
38	Comment on "Hypogonadotrophic hypogonadism due to a mutation in the luteinizing hormone β-subunit gene". *Korean Journal of Internal Medicine*, **2017**, 32, 566-567	2.5	2
37	Tumor cells may circulate in medullary thyroid cancer patients independently of serum calcitonin. *Endocrine-Related Cancer*, **2018**,	5.7	2
36	Shrinkage of pituitary adenomas with pasireotide. *Lancet Diabetes and Endocrinology,the*, **2019**, 7, 509	18.1	2

35	Challenges and controversies in the treatment of prolactinomas. *Expert Review of Endocrinology and Metabolism*, **2014**, 9, 593-604	4.1	2
34	Characteristics of familial isolated pituitary adenomas. *Expert Review of Endocrinology and Metabolism*, **2007**, 2, 725-733	4.1	2
33	Association of acute leukemia and autoimmune polyendocrine syndrome in two kindreds. *Leukemia* , **2003**, 17, 1912-4	10.7	2
32	Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study. *European Journal of Endocrinology*, **2021**, 185, 863-873	6.5	2
31	Gen□ica en adenomas hipofisarias: ¿qu□ c□ho y a qui□?. *Endocrinologia, Diabetes Y Nutrici□*, **2019**, 66, 71-73	1.3	1
30	Absence of hypogonadism in a male patient with a giant prolactinoma: a clinical paradox. *Annales D□Endocrinologie*, **2008**, 69, 47-52	1.7	1
29	Pituitary Tumors Associated With Multiple Endocrine Neoplasia Syndromes **2019**, 642-647		1
28	Familial Pituitary Adenomas: An Overview **2013**, 103-112		1
27	A Hard Look at Cardiac Safety with Dopamine Agonists in Endocrinology. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e2452-e2454	5.6	1
26	Expression of Peroxisome Proliferator-Activated Receptor alpha (PPAR□in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells. *Molecular and Cellular Endocrinology*, **2016**, 426, 61-72	4.4	1
25	Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantism.. *American Journal of Human Genetics*, **2022**,	11	1
24	Complicated Clinical Course in Incipient Gigantism Due to Treatment-resistant Aryl Hydrocarbon Receptor□nteracting Protein□utated Pediatric Somatotropinoma. *AACE Clinical Case Reports*, **2021**,	0.7	1
23	Thyroid cancer in the Democratic Republic of the Congo: Frequency and risk factors. *Annales D□Endocrinologie*, **2021**, 82, 606-612	1.7	0
22	Somatostatin Analogs in the Gastrointestinal Tract **2006**, 1131-1138		0
21	Genetic Testing in Pituitary Adenomas: What, How, and In Whom?. *Endocrinolog□ Diabetes Y Nutrici□ (English Ed)*, **2019**, 66, 71-73	0.1	
20	Prognostic Factors: Molecular Pathway □Tumour Suppressor Gene (MEN1) **2018**, 135-148		
19	Advances in diagnosis and management of familial pituitary adenomas. *International Journal of Endocrine Oncology*, **2016**, 3, 313-323	0.3	
18	Genetics of Pituitary Gigantism: Syndromic and Nonsyndromic Causes. *Endocrinology*, **2019**, 1-21	0.1	

17	A bittersweet symphony. *Endocrine-Related Cancer*, **2014**, 21, C7-9	5.7
16	Professor Rolf C. Gaillard. *Pituitary*, **2012**, 15, 465	4.3
15	Functioning Pituitary Adenomas **2010**, 55-65	
14	Current and future perspectives on recombinant growth hormone for the treatment of obesity. *Expert Review of Endocrinology and Metabolism*, **2008**, 3, 75-90	4.1
13	Does the nadir growth-hormone level predict response to somatostatin-analogue therapy?. *Nature Clinical Practice Endocrinology and Metabolism*, **2006**, 2, 12-3	
12	Genetics of Pituitary Gigantism: Syndromic and Nonsyndromic Causes. *Endocrinology*, **2019**, 1-21	0.1
11	De la g□□ique des ad□omes hypophysaires familiaux. *Bulletin De L'Academie Nationale De Medecine*, **2009**, 193, 1557-1571	0.1
10	Genetic Causes of Familial Pituitary Adenomas **2011**, 137-150	
9	The Role of Aryl Hydrocarbon Receptor (AHR) and AHR-Interacting Protein (AIP) in the Pathogenesis of Pituitary Adenomas **2013**, 189-201	
8	Differentiated thyroid carcinoma in sporadic and familial presentations of acromegaly: A case series. *Annales D'Endocrinologie*, **2020**, 81, 482-486	1.7
7	Functioning Pituitary Adenomas **2016**, 79-91	
6	Medical management of pituitary gigantism and acromegaly **2021**, 245-257	
5	Gigantism: clinical diagnosis and description **2021**, 39-52	
4	History of the identification of gigantism and acromegaly **2021**, 1-16	
3	Acromegaly: clinical description and diagnosis **2021**, 53-78	
2	Genetics of Pituitary Gigantism: Syndromic and Nonsyndromic Causes. *Endocrinology*, **2021**, 291-311	0.1
1	Gigantism Remains a Clinical Challenge. *Archives of Iranian Medicine*, **2015**, 18, 871	2.4